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Alan McHughen (University of California-Riverside, Riverside).  Patricia, thank you 
very much for your overview of the Canadian situation. I’m curious to know how many 
genetically engineered plants cultivated in Canada are not considered PNTs1, and so 
didn’t go through your approval system?
Patricia McAllister:  There are none.
McHughen:  Then, I’m confused about what your definition of a novel plant is. With Bt 
corn in the United States, of course we use event by event. It sounds like that’s what you 
do in Canada as well, which would seem to be contrary to the PNT concept. 
McAllister:  At this point, all genetically engineered products that have been put forward 
have met the definition of a plant with a novel trait. The ones we have that are more 
unique are the ones that we regulate that the US wouldn’t regulate. For instance, turf grass 
without question would have hit a novelty trigger in Canada. And we have sunflowers, 
lentils and wheat that are herbicide tolerant that were not developed through genetic 
engineering, and those ones are regulated in Canada as PNTs. So, we capture a broader 
number of products.
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McHughen:  Right, you capture more in terms of the mutagenesis and non-recombinant 
things. I recognize that and appreciate that, but I also thought that the point of the plant-
with-novel-trait product trigger was so that once you get an event through—a Bt corn, 
for example—the next Bt-corn event would not be considered novel. How do you then 
define the second and third and subsequent Bt-corn varieties as being novel?
McAllister:  There is certainly a lot of talk about where it will go, but at this point each 
one is triggering the regulations as it comes through.
McHughen:  Is there something in the trait? I’m confused about that now because I 
thought that the system was developed in Canada so that subsequent things that don’t 
have new traits would not be captured. What is the scientific basis for a new trait that 
is the trigger? 
McAllister:  I am unable to answer that question. I have been with this group since Sep-
tember and my job has mostly been issues management. A few things—like alfalfa—have 
created havoc for us. I was not part of the development of these regulations and I simply 
work with what we are given. But, believe me, our major players are frequently asking 
us, When are you going to the “me too” products—when you’ve already looked at a trait? They 
certainly can go into conventional breeding. We don’t have to approve individual varieties, 
but, if you are modifying your event, we are still going back and looking at it again.
Julie Svetlik (Texas A&M AgriLife Research, College Station):  I think Patricia already 
answered this question for me—thank you—so the question is for the US agencies. As-
suming a plant or product has cleared the regulatory process in your agency and has been 
authorized and has entered the market, are there procedures in place at your agency to 
reevaluate status if new data come out that indicate that the plant or the product is not 
safe for humans or the environment? 
David Heron:  I’ll go first since ours looks like once our hands are off, they are always 
off—but if new evidence demonstrates a risk as a plant pest, then we do have the authority 
to bring it back under the regulation. We have not seen that yet.
Robert Merker:  We have seen a number of instances in which new data have been brought 
back to us at some point or other, but it has always been data that do not change the 
final conclusion of safety.
Chris Wozniak:  Our statute is a bit different. FIFRA is a licensing statute, so as long as 
you want to distribute, sell or use that pesticide in the United States, then you are under 
the license, meaning you pay an annual maintenance fee, you have to supply reports on 
sales figures, etc. But you are also beholden to a clause referred to as “6(a)(),” where, if 
there are any adverse effects—and that is determined by the agency not by the individual 
so much—anything unusual has to be reported to the agency in a timely manner and we 
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maintain a database of what we call “6(a)() events” and determine whether they require 
follow up. In addition to that, because it is a license, all of the registrations have a term 
of expiration and these will vary. For example, with the Bts, part of it depends on the 
durability of the product. The product seen as being durable in terms of resistance to 
insects might get a 0- or -year registration. If it’s a single-trait product, it’s more likely 
to get a 3- or 4-year registration and, at those times, they are reassessed and they may 
enter what is called a re-registration or re-review process, where people basically look at 
the literature and look at what is known, and anything else that may have come up since 
the initial registration and then make a determination of whether data ars required. We 
have a process that is called “data calling,” where, if something comes up, we can request 
that information.
Robert Wager (Vancouver Island University, Nanaimo):  Each of you, in your own way, 
has mentioned that GM crops and non-GM crops with similar traits are regulated roughly 
the same way. My question goes to Cry proteins, and it appears to be that that’s not 
 always the case where you have significant regulatory requirements for a GM crop with a 
particular Cry protein engineered into it, whereas I don’t seem to see—perhaps I’m wrong 
on this—any real regulations involving using the in vivo whole bacterium expressing the 
same proteins and I’d like to understand if, in fact, that is true and, if so, why ?
Wozniak:  If you are speaking in terms of using either a spore or spore-plus-cell prep as a 
biopesticide—yeah, we certainly regulate those. We have both engineered and non-engi-
neered forms of Bt as well as dozens of other microbes for use as insecticides, nematicides 
and even some as herbicides. So I’m not sure why you are picking on Bt. Any microbial 
agent, whether it’s a virus, bacteriophage, protozoan, alga or fungus, that has a pesticidal 
claim associated with it—in other words preventing, destroying or repelling some disease 
or pest—is a pesticide under our law. I think, at last count, we have 97 active ingredients 
and from those stem hundreds of products.
McAllister:  From the Canadian perspective, those would not be regulated by the Canadian 
Food Inspection Agency, but would be regulated through Health Canada’s Pest Manage-
ment Regulatory Agency.
Bob Avant (Texas AgriLife Research, College Station):  Recently, the USDA said they are 
going to go into a full blown EIS evaluation of new genetically engineered events, and I 
would like to hear some conversation: does that really change much about what we are 
doing? Is it going to delay the process? The conventional wisdom is, anytime an EIS is 
required it costs millions of dollars, it takes years to do and it’s a good way of delaying 
things. Does it represent any change or is it just another hurdle we are going to have to 
cross to get down the path?
Heron:  As far as whether everything is going to require an EIS, no it won’t. An EIS, 
for those of you unfamiliar, I referred to as environmental assessments under NEPA, 
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the National Environmental Policy Act. If an agency cannot come to a finding of “no 
significant impact on the environment” when they do an environmental assessment, if 
they want to proceed with considering the action, then they can go to an environmental 
impact statement, which is a more involved process and, like the environmental assess-
ment, has public involvement. The agency has interaction with the public throughout 
the process. But, the fact that these are now being open for public comment on the 
process called “scoping” to see the extent of the environmental impact statement, it does 
not mean that it is going to happen for all. These were seen as issues that are very closely 
related and it would be difficult to consider them separately. The decision on whether 
federal agencies choose environmental impact statements or environmental assessments 
is rather complex. It involves legal reviews with the department, interaction with the 
Council on Environmental Quality, which is a lighthouse that takes a look at NEPA and 
its obligations to federal agencies. Maybe that’s a long way of saying that no, this is not 
going to be the standard and yes, it is a more involved process.
Bill McCutchen (Texas AgriLife Research, College Station):  A scenario here for you to 
think about. What would be the steps if, let’s say, a spinoff company from Texas A&M 
or another university were put in place for a specialty crop whereby—and I know this is 
a big “if ”—if we had freedom to operate and we had a license for a previously approved 
herbicide and or Bt gene and we wanted to put that into onions or another vegetable, 
would we be required to go through the entire process again in terms of digestibility, 
allergenicity? Because, a big expense is the non-target organism piece—doing the types 
of tests that require, as you know, a lot of work and money. So, would it be possible to 
license from Monsanto or DuPont, let’s say a spinoff company for our university of a 
previously approved gene for herbicide and insect resistance and assuming we had freedom 
to operate for agrotransformation, etc., what would be required?
Heron:  We regulate organisms. We don’t regulate genes. Congress set out the definition of 
a plant pest, so that sets the parameters. When we are making a decision for non-regulated 
status it’s for the organism. It’s not for the gene. The information we may have in looking 
at a gene in another organism may inform our review subsequently but that would not 
mean that you don’t come in if you take a Bt or herbicide tolerance cassette and put it in 
onion instead of cotton. The onion would still come through us.
McCutchen: I understand that. I’ve been through this process many times in a former 
life, but if this has already gone through tox tests, non-target organisms, from a scientific 
standpoint—I understand there is law and regulation—why can’t we get together and 
streamline some of these things and help our producers help themselves? Can we work 
across agencies and with institutes to develop new products that aren’t so new but are in 
different vehicles if you will?
McAllister:  From the Canadian perspective, if we are more familiar with things it can 
make it easier. It’s how you can communicate your story, but, in reality, you would need 
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to speak directly to our specific assessment group. If it’s in a new plant, it’s definitely going 
to be assessed as a new product, but whether you’d have to redo the allergenicity data 
and the other toxicity data for genes that we are very familiar with, that would require a 
very specific discussion.
Wozniak:  Where it truly is the same gene and not some modification or a similar type 
gene, there is a process called “data compensation” where you can compensate the com-
pany that originally submitted supporting data. So that’s one avenue. In terms of the 
environmental side of the equation where you are looking at non-target effects, if you 
are changing the exposure scenario then it is likely you are going to have to look at some 
data generation for specific pests. In other words, the beneficial insects you choose that 
might be representative of a corn field in Iowa may not be the same as that represented 
by an onion in Texas. So that would be up to the risk assessor to determine what types 
of studies would have to be generated de novo and which ones could be bridged. We do 
occasionally bridge data, particularly so with microbial agents, but certainly it’s plausible 
with some of the PIPs. Now, as for the larger question in getting away from event by 
event transformation even within the same species, you can take a PIP that’s been regis-
tered in field corn and do the appropriate crosses, you know, typical sexual, traditional 
breeding crosses, move it into popcorn, and you are covered as far as the tolerance goes 
and all that. However, one of the arguments that has been made—and I’m not saying I 
agree with it 00 per cent—but if you generate a new event through transgenesis, either 
through Agrobacterium or the gene gun or whatever your mechanism, then your position 
within the genome, as far as where your transgene inserts, can influence the pattern of 
gene expression. So, in our case, one of the things that we look at relative to non-target 
effects but also just for the overall accumulation of your pesticidal substance, which needs 
to be recorded on a confidential statement, that requires an assessment. You know, is it 
identical just because you used the same promoter and the same open reading frame and 
the same termination sequence if it’s in two different crops or even within the same crop 
but it’s in two different positions? That’s the crux of the argument. At what point do 
you say, Well, we’ve seen this enough and the likelihood of that happening is small enough, I 
think that, in some respects, is what we are moving toward, but as far as going between 
different species, like, say, onion and corn, that’s a larger question.
Merker:  I defer to EPA on pesticide issues, but, for food and feed safety, if we’ve seen the 
proteins before, essentially we’ve seen the proteins before. The allergenicity assessment 
and the assessment for toxicity would be the same and could be done either by incorpo-
ration by reference or by summarizing what information we had seen before and where 
we could find it. Certainly we wouldn’t make somebody do that over again, and, as a 
for instance, if you were dealing with our favorite antibiotic resistance marker, NPTII, 
we actually approved that as a food additive, and even if you were using it in one of the 
crops for which it wasn’t approved, if you pointed us to that approval, certainly we would 
want to know the specifics of how it got integrated, but the safety of the protein could 
be referred back to our regulation.
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Wozniak:  One thing I want to clarify—just to make sure—there is a difference between 
what’s ruled under FFDCA like the tolerance action, versus what’s under FIFRA, which 
would cover, for example, non-target effects but also human health effects. So, for example, 
if you are working with CryAc as your insecticidal protein and it’s already covered by 
a tolerance, then you don’t have to redo the studies that are associated with that toler-
ance. It could be an oral tox test, allergenicity, etc. However, on the FIFRA side, if the 
concern is more about exposure of non-targets then that is where the data compensation 
would come in—where you would likely pay another company to utilize their previously 
submitted and accepted data.
Charles Rinerson (Texas AgriLife Research, College Station):  Dr. Merker, the basis for 
the consultation and regulation you were talking about earlier was based on the FD&C 
Act. Do you see a different consultation process or considerations if the plant or product 
were regulated under the DSHEA Act2?
Merker:  Certainly, if it comes in for something in a dietary supplement, and there has 
been a history of exactly one of those coming in. It may fit the criteria for consideration 
as a new dietary ingredient and it would be the substance going into the dietary supple-
ment that would need to be looked at, not necessarily the whole crop.
Roger Beachy (Global Institute for Food Security, Saskatoon): I’d like to take us back 
just a bit—and maybe this is too big a question to answer today—but, in 987, when 
the coordinated framework was developed, it was expected that there would be a full 
reexamination of the coordinated framework in some period of time, 7 to 0 years, and 
that we would learn from those 7 to 0 years about what to go forward with. In fact, 
some of the original challenges were to try to eliminate regulations based on what we’d 
learned in the first 0 years. We haven’t done that yet. We’ve learned more about what to 
regulate, what we think we know about to regulate, but in fact, regulation is not simpli-
fied, it’s made more difficult because we keep adding more on each time someone raises a 
possibility of potential damage or danger. When is it time to re-evaluate the coordinated 
framework and come up with a new framework? We are now more than 0 years in and 
we haven’t re-evaluated. When is it time to take the learnings of science since 987 and 
redo the coordinated framework based upon what we’ve learned and what we expect 
to see in the following two or three decades? I ask the question because most of us feel 
that, given what happened in 987— and I was involved in that process too—but Nina 
Fedoroff and others have reminded us that this is the way that we would start, but we 
expected to deregulate it more fully and make it easier to innovate, and it’s not. I do 
 appreciate the learnings and the ability to cross back and go back to old data and restate 
them. It should help Texas A&M to simplify, but it’s still a more expansive program than 
had been imagined in 987.  Can you help me understand where we might be in 5 or 
0 more years?
2Dietary Supplement Health and Education Act.
79
Merker:  I don’t think—from FDA’s point of view—that it really has changed. I actually 
think that our 99 policy is pretty flexible. Certainly, it’s a situation where if the 
 developer wants to seek us out they can and we are available. And the issues are going to 
be the same: safety and nutrition. As long as those get covered we are happy to consider 
things. We actually didn’t think we would be doing this for this long, but the developers 
seem to want it, I think mainly for international trade issues, and the public seems to 
want it as well.
Heron:  Yeah, that’s an interesting point because, actually in 99, OSTP3 put out a 
second document that was actually calling for what you are saying here Roger, to dial 
it back wherever possible. What I have seen is that unless there is a sustained push in a 
certain direction it doesn’t happen, so the status quo stays in place. And so, at the regula-
tory agencies, we try to run the mousetrap as best we can whether the mousetrap itself 
has a faulty design, that has to come from outside. I mean, this administration with the 
Holdren memo, has restated the principles of the Reagan administration. But, in terms of 
what it actually means in practice—and this is where the distinction between what is in 
the law and what is placed in regulation and how that works—you can see now that this 
whole premise of presumed innocence of things developed through genetic engineering 
has been turned on its head, and so now we are trying to prove a lack of harm, which we 
all know is impossible to do.
Wozniak:  Certainly, I understand your frustration with the lack of change. I think Dave 
Heron makes an excellent point though, in that it is the actual practice of what is per-
formed, in terms of regulation or deregulation or consultation, depending on the agency. 
But, in terms of the coordinated framework, I don’t think it’s a bad idea to reassess that. 
One of the decisions that was made was to use existing statutes to cover the bases and 
I’m not going to voice an opinion one way or the other on whether that was a smart 
idea, but what I will say is that some of the changes that you are talking about require 
legislative action and have to be done on Capitol Hill, not at EPA or APHIS or FDA, 
unfortunately. And I think that’s part of the frustration, but, again, Dave’s point: those 
changes require forward-thinking people who aren’t afraid to take some risk and perhaps 
some backlash from the public in terms of making some bold moves. Now, one of the 
things that we have heard about—and it’s very obvious to everyone in this room—the 
lawsuits, for example, that APHIS has had to endure over these last years are always part 
of the battle. If you try to be progressive and say, Well, we’ve seen this enough we don’t 
 really need to regulate this, there are going to be a whole bunch of people on the other side 
who say, Oh yes you do. The Federal Register notices get 50,000 to 60,000 comments, etc. 
But I think you are right that it certainly is time to move forward and use some of the 
familiarity we have with these products such that, even if we do regulate them, we do 
it a much reduced level—basically you would be more cataloging them than regulating 
them. Again, it’s going to take somebody with a bold heart who is willing to take a beat-
3Office of Science and Technology Policy.
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ing to move that forward. Certainly, there is still the issue—although I don’t think it’s an 
insurmountable one—where I talk with a lot of foreign governments and it makes them 
very nervous to think that we’re going to have certain things that aren’t really scrutinized 
properly, but some of the companies also tell me, Don’t worry about that. We’ll deal with 
those individual countries in terms of trade. We’ll work around whatever their requirements 
are. I want to mention one of the proposals we are considering, or reconsidering, and 
that is a cisgenic exemption with cisgenics defined a little bit more broadly than perhaps 
is done in the literature. We are in the early stages of reviving that, which is part of a 
previous data-requirements rule that never got off the ground a few years back. So, that’s 
one instance where, I think, philosophically, it’s a major move for the agency to consider 
a product of recombinant DNA that doesn’t require regulation. It’s not going to solve the 
problem for everybody for sure. Those people who still rely on basic transgenesis with 
foreign genes—it’s not going to help them one iota, except in terms of moving that ball 
forward and saying, Here’s something where we don’t have to be concerned just because it’s 
genetically engineered.
